Novozymes A/S

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Novozymes strengthens and expands position in human health and functional foods by acquiring a majority stake in Synergia Life Sciences

ICL-Israel Chemicals

ICL vs. NVZMY: Which Stock Is the Better Value Option?

ICL vs. NVZMY: Which Stock Should Value Investors Buy Now?

Novozymes (NVZMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Novozymes (NVZMY) Ahead of Earnings?

Novozymes A/S (NVZMF) CEO Ester Baiget on Q3 2021 Results - Earnings Call Transcript

Novozymes delivered 7% organic sales growth in the third quarter and 6% organic sales growth in the first nine months of 2021. Due to stronger performance the company has upgraded its full-year financial guidance from previously 4-6% organic sales growth to 5-6% and an EBIT margin of around 27%, from previously around 26%.

Novozymes is unlocking growth by delivering strong Q3 results and increasing full-year guidance

ICL or NVZMY: Which Is the Better Value Stock Right Now?

With the launch of “Unlocking Growth – Powered by Biotech” Novozymes presents its 2025-strategy. It sets out an organic sales growth target of 5+% CAGR for the 5-year period until 2025, coupled with the ambition to double the company's revenue by 2030. COPENHAGEN, DENMARK – 27 September 2021 – “Unlocking Growth – Powered by Biotech” is Novozymes' strategy towards 2025 based on the solid foundation and successful execution of “Better Business with Biology”. As part of ‘Unlocking Growth' Novozymes is further cementing its position as a Biotech Powerhouse by leveraging and investing in its unique knowledge and position in biological innovation, scale-up, customer interaction, and new high-growth opportunities.

Novozymes is unlocking growth with the ambition of doubling company revenue by 2030

Univar

Univar (UNVR) and Novozymes join forces to deliver sustainable solutions waste and wastewater treatment using advanced biotechnology.

Univar (UNVR) & Novozymes Tie-Up for Bio Solutions for Wastewater

To feed a growing population, Novozymes is inviting all interested parties to help co-create and innovate the future of sustainable protein. By combining science with business expertise Novozymes wants to rethink how protein is made and sourced by enabling a new and progressive industry to provide sustainable nutrition.

Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably

Please read the full announcement in the attached PDF

Novozymes' financial calendar 2022

Novozymes A/S (NVZMF) CEO Ester Baiget on Q2 2021 Results - Earnings Call Transcript

Novozymes delivered 9% organic sales growth in the second quarter and 6% organic sales growth in the first half of 2021. The company has narrowed its full-year financial guidance from previously 2-6% and now expects organic sales growth of 4-6% and an EBIT margin of ~26%, from previously 25-26%.

Novozymes delivers strong Q2 results and narrows full-year guidance to the high-end of the range

Novozymes reaches a strategic milestone in the implementation of its strategy with a significant entry into Advanced Protein Solutions

Novozymes A/S (NVZMF) CEO Ester Baiget on Q1 2021 Results - Earnings Call Transcript

Novozymes delivered 3% organic sales growth in the first quarter of the 2021 financial year and an EBIT margin of 29.6%. The company maintains its full-year financial guidance.

Novozymes delivers solid Q1 results with 3% organic sales growth and strong earnings

Univar (UNVR) and Novozymes' partnership signifies a shared dedication toward providing customers with a portfolio of ingredients designed to help improve product performance.

Univar (UNVR) Inks Exclusive Distribution Deal With Novozymes

The acquisition of Biota's successful microbiome R&D team and data science platform strengthens Novozymes' leading microbe innovation capability and will be a force-multiplier of the company's current probiotic development activities and recent acquisitions in the consumer health industry.

Novozymes acquires data science platform of Biota to strengthen microbiome R&D capabilities in probiotic development

Novozymes A/S' Annual Shareholders' Meeting 2021

Invitation to Novozymes' annual shareholders' meeting 2021

Novozymes A/S (NVZMF) CEO Ester Baiget on Q4 2020 Results - Earnings Call Transcript

Novozymes delivered flat organic sales growth in the 2020 financial year and an EBIT margin of 26.1%. In 2021 the company expects 2-6% organic growth supported by innovation, stronger commercial presence, and gradual industry recovery. EBIT margin is expected at a solid 25-26%.

Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021

Novozymes completes acquisition of Microbiome Labs

Novozymes acquires Microbiome Labs

Novozymes A/S (NVZMF) CEO Ester Baiget on Q3 2020 Results - Earnings Call Transcript

Transactions under Novozymes’ stock buyback program

News for Novozymes A/S Stock (NVZMY)